Lonza readies as pharma sector boosts Singapore production

A pharma production boost offset slumping electronics manufacturing, giving Singapore its biggest industrial production surge in 5 months. Pharmaceutical output soared 157%, while electronics production declined 22% compared with a year earlier.

For Singapore, it translates into a 22% industrial production increase over a year ago, according to its Economic Development Board, as reported by Bloomberg.

Manufacturing accounts for more than 20% of Singapore's economy, the report says. The question for economists is whether the August performance is a fluke, the start of a trend, or something else.

Contract manufacturer Lonza, for one, appears to see plenty of potential there. In the last few months, the CMO has announced a $12 million plan to expand its biopharmaceutical development services platform in Singapore and plans a secondary listing on the Singapore Stock Exchange.

- here's the story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.